Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label drug-drug interaction study of PRAX-628 in healthy participants
NL-OMON59652Phase 1Completed
- Sponsor
- Praxis Precision Medicines
- Start
- Aug 2024
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vormatrigine in epilepsy, sponsored by Praxis Precision Medicines. Primary endpoint: Primary endpoint(s). Started Aug 2024; status: completed.
02
Drugs
vormatrigine
03
Conditions
epilepsy
Beyond the preview
Go deeper on NL-OMON59652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59652.